THERIVA BIOLOGICS INC Financials

TOVX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows THERIVA BIOLOGICS INC (TOVX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

THERIVA BIOLOGICS INC passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, THERIVA BIOLOGICS INC generates $0.66 in operating cash flow (-$16.9M OCF vs -$25.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$26.2M

YoY-23.1%

THERIVA BIOLOGICS INC's EBITDA was -$26.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 23.1% from the prior year.

Free Cash Flow

-$16.9M

YoY+11.8%

THERIVA BIOLOGICS INC generated -$16.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 11.8% from the prior year.

Net Income

-$25.7M

YoY-39.8%

THERIVA BIOLOGICS INC reported -$25.7M in net income in fiscal year 2024. This represents a decrease of 39.8% from the prior year.

EPS (Diluted)

$-19.03

THERIVA BIOLOGICS INC earned $-19.03 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.2% from the prior year.

Cash & Debt

$11.6M

YoY-49.9%

5Y CAGR-5.1%

10Y CAGR-4.0%

THERIVA BIOLOGICS INC held $11.6M in cash against $92K in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

THERIVA BIOLOGICS INC had 3M shares outstanding in fiscal year 2024. This represents an increase of 305.5% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$12.0M

YoY-15.9%

5Y CAGR+1.7%

10Y CAGR-1.8%

THERIVA BIOLOGICS INC invested $12.0M in research and development in fiscal year 2024. This represents a decrease of 15.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1K

YoY-99.5%

10Y CAGR-32.1%

THERIVA BIOLOGICS INC invested $1K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 99.5% from the prior year.

TOVX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$12.0M-15.9%	$14.3M+22.1%	$11.7M+50.3%	$7.8M+52.0%	$5.1M-53.7%	$11.1M
SG&A Expenses	$7.4M+3.9%	$7.1M-27.8%	$9.9M+52.3%	$6.5M+28.7%	$5.0M+9.8%	$4.6M
Operating Income	-$26.3M-22.9%	-$21.4M+0.7%	-$21.6M-51.2%	-$14.3M-40.5%	-$10.2M+35.1%	-$15.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0+100.0%	-$1.6M-15.1%	-$1.4M	$0	$0	$0
Net Income	-$25.7M-39.8%	-$18.3M+6.8%	-$19.7M-38.0%	-$14.3M-42.1%	-$10.0M+34.4%	-$15.3M
EPS (Diluted)	$-19.03	$-28.48	$-1.31+31.1%	$-1.90-187.9%	$-0.66	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M+30.6%	$2.0M-34.2%	$3.0M	N/A	$2.7M-7.4%	$3.0M-14.6%	$3.5M	N/A
SG&A Expenses	$1.9M-83.1%	$11.2M+671.5%	$1.4M	N/A	$2.3M+56.9%	$1.5M-24.1%	$1.9M	N/A
Operating Income	-$4.4M+66.2%	-$13.1M-197.3%	-$4.4M	N/A	-$7.9M+7.1%	-$8.5M-57.4%	-$5.4M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.4M+66.6%	-$13.1M-202.0%	-$4.3M-2.3%	-$4.2M+45.3%	-$7.7M+7.1%	-$8.3M-61.0%	-$5.2M-283.7%	$2.8M
EPS (Diluted)	$-0.45	$-1.93	$-1.55	N/A	$-6.81	$-10.72-42.4%	$-7.53	$0.76

TOVX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$35.4M-36.0%	$55.2M-23.2%	$71.9M+2.1%	$70.4M+736.7%	$8.4M-51.2%	$17.2M
Current Assets	$16.3M-40.6%	$27.4M-39.8%	$45.5M-33.9%	$68.9M+767.9%	$7.9M-51.7%	$16.4M
Cash & Equivalents	$11.6M-49.9%	$23.2M-44.5%	$41.8M-37.9%	$67.3M+981.2%	$6.2M-58.6%	$15.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$0-100.0%	$5.7M+3.2%	$5.5M	$0	N/A	N/A
Total Liabilities	$16.3M+4.9%	$15.5M-10.3%	$17.3M+248.9%	$5.0M-62.4%	$13.2M-14.5%	$15.4M
Current Liabilities	$7.6M+12.6%	$6.7M-4.6%	$7.1M+98.6%	$3.6M+19.8%	$3.0M-43.8%	$5.3M
Long-Term Debt	$92K-43.2%	$162K-26.7%	$221K	N/A	N/A	N/A
Total Equity	$19.1M-48.4%	$37.0M-28.7%	$51.8M-20.8%	$65.4M+1472.1%	-$4.8M-361.8%	$1.8M
Retained Earnings	-$335.0M-8.3%	-$309.3M-6.3%	-$291.0M-7.3%	-$271.3M-9.3%	-$248.1M-5.3%	-$235.5M

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Total Assets	$30.8M-13.9%	$35.8M+11.4%	$32.2M-9.0%	$35.4M-11.9%	$40.1M-5.4%	$42.4M-13.0%	$48.7M-11.8%	$55.2M
Current Assets	$9.9M-32.8%	$14.7M+18.2%	$12.5M-23.4%	$16.3M-16.6%	$19.5M-0.9%	$19.7M-9.0%	$21.7M-21.0%	$27.4M
Cash & Equivalents	$7.5M-37.9%	$12.1M+21.0%	$10.0M-13.7%	$11.6M-29.3%	$16.4M-1.1%	$16.6M-9.1%	$18.3M-21.2%	$23.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0	N/A	$1.5M-73.7%	$5.6M-2.2%	$5.7M
Total Liabilities	$24.1M-4.4%	$25.2M+51.3%	$16.7M+2.3%	$16.3M+5.2%	$15.5M+4.9%	$14.7M+0.9%	$14.6M-5.9%	$15.5M
Current Liabilities	$11.0M-11.2%	$12.4M+52.1%	$8.1M+7.4%	$7.6M+3.6%	$7.3M+6.9%	$6.8M+14.0%	$6.0M-10.8%	$6.7M
Long-Term Debt	N/A	N/A	N/A	$92K	N/A	N/A	N/A	$162K
Total Equity	$6.7M-36.6%	$10.6M-31.5%	$15.5M-18.7%	$19.1M-22.6%	$24.6M-4.9%	$25.9M-17.5%	$31.4M-15.1%	$37.0M
Retained Earnings	-$356.7M-1.2%	-$352.4M-3.8%	-$339.3M-1.3%	-$335.0M-1.3%	-$330.5M-2.4%	-$322.8M-2.6%	-$314.5M-1.7%	-$309.3M

TOVX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$16.9M+10.8%	-$19.0M+0.5%	-$19.1M-48.0%	-$12.9M-5.9%	-$12.2M+12.3%	-$13.9M
Capital Expenditures	$1K-99.5%	$202K+74.1%	$116K+728.6%	$14K+55.6%	$9K	$0
Free Cash Flow	-$16.9M+11.8%	-$19.2M0.0%	-$19.2M-48.8%	-$12.9M-6.0%	-$12.2M+12.2%	-$13.9M
Investing Cash Flow	-$1K+99.5%	-$202K+95.4%	-$4.4M-31300.0%	-$14K-55.6%	-$9K	$0
Financing Cash Flow	$5.5M+779.4%	$625K+132.4%	-$1.9M-102.6%	$74.0M+2103.1%	$3.4M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$288K	$0	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Operating Cash Flow	-$4.3M+8.3%	-$4.7M+0.9%	-$4.8M-1.4%	-$4.7M-19.9%	-$3.9M-13.4%	-$3.5M+29.3%	-$4.9M+25.4%	-$6.5M
Capital Expenditures	$19K+11.8%	$17K+325.0%	$4K	$0	$0-100.0%	$10K+233.3%	$3K-94.6%	$56K
Free Cash Flow	-$4.3M-31.0%	-$3.3M+4.7%	-$3.5M+25.9%	-$4.7M-19.9%	-$3.9M-138.2%	-$1.6M+1.3%	-$1.7M+74.8%	-$6.6M
Investing Cash Flow	-$19K-11.8%	-$17K-325.0%	-$4K	$0	$0	$0	$0+100.0%	-$56K
Financing Cash Flow	-$148K-102.2%	$6.8M+121.7%	$3.1M+43785.7%	$7K-99.8%	$3.7M	$0	$0+100.0%	-$1.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TOVX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-72.6%-39.3pp	-33.2%-5.8pp	-27.4%-7.1pp	-20.3%+99.1pp	-119.4%-30.6pp	-88.8%
Current Ratio	2.15-1.9	4.07-2.4	6.45-12.9	19.37+16.7	2.67-0.4	3.11
Debt-to-Equity	0.000.0	0.000.0	0.00-0.1	0.08+2.8	-2.76-11.2	8.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-14.1%+22.3pp	-36.4%-23.0pp	-13.4%+12.6pp	-26.0%-6.7pp	-19.3%+0.4pp	-19.6%-9.0pp	-10.6%-25.5pp	14.9%
Current Ratio	0.90-0.3	1.19-0.3	1.53-0.6	2.15-0.5	2.67-0.2	2.88-0.7	3.60-0.5	4.07
Debt-to-Equity	3.58+1.2	2.37+1.3	1.08+1.1	0.00-0.6	0.63+0.1	0.57+0.1	0.47+0.5	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xortx Therapeutics Inc XRTX

$2.7M

Galecto Inc. GLTO

$1.8B

Entero Therapeutics ENTO

$10.1M

Quoin Pharmaceuticals Ltd QNRX

$15.2M

Azitra Inc AZTR

$1.9M

Frequently Asked Questions

Is THERIVA BIOLOGICS INC profitable?

No, THERIVA BIOLOGICS INC (TOVX) reported a net income of -$25.7M in fiscal year 2024.

What is THERIVA BIOLOGICS INC's earnings per share (EPS)?

THERIVA BIOLOGICS INC (TOVX) reported diluted earnings per share of $-19.03 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is THERIVA BIOLOGICS INC's EBITDA?

THERIVA BIOLOGICS INC (TOVX) had EBITDA of -$26.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does THERIVA BIOLOGICS INC have?

As of fiscal year 2024, THERIVA BIOLOGICS INC (TOVX) had $11.6M in cash and equivalents against $92K in long-term debt.

What is THERIVA BIOLOGICS INC's free cash flow?

THERIVA BIOLOGICS INC (TOVX) generated -$16.9M in free cash flow during fiscal year 2024. This represents a 11.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is THERIVA BIOLOGICS INC's operating cash flow?

THERIVA BIOLOGICS INC (TOVX) generated -$16.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are THERIVA BIOLOGICS INC's total assets?

THERIVA BIOLOGICS INC (TOVX) had $35.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are THERIVA BIOLOGICS INC's capital expenditures?

THERIVA BIOLOGICS INC (TOVX) invested $1K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does THERIVA BIOLOGICS INC spend on research and development?

THERIVA BIOLOGICS INC (TOVX) invested $12.0M in research and development during fiscal year 2024.

How many shares does THERIVA BIOLOGICS INC have outstanding?

THERIVA BIOLOGICS INC (TOVX) had 3M shares outstanding as of fiscal year 2024.

What is THERIVA BIOLOGICS INC's current ratio?

THERIVA BIOLOGICS INC (TOVX) had a current ratio of 2.15 as of fiscal year 2024, which is generally considered healthy.

What is THERIVA BIOLOGICS INC's debt-to-equity ratio?

THERIVA BIOLOGICS INC (TOVX) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is THERIVA BIOLOGICS INC's return on assets (ROA)?

THERIVA BIOLOGICS INC (TOVX) had a return on assets of -72.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is THERIVA BIOLOGICS INC's cash runway?

Based on fiscal year 2024 data, THERIVA BIOLOGICS INC (TOVX) had $11.6M in cash against an annual operating cash burn of $16.9M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is THERIVA BIOLOGICS INC's Piotroski F-Score?

THERIVA BIOLOGICS INC (TOVX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are THERIVA BIOLOGICS INC's earnings high quality?

THERIVA BIOLOGICS INC (TOVX) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.